Abbott Laboratories ABT recently announced FDA approval for its latest version of MitraClip heart valve repair device to treat mitral regurgitation (MR). With the approval for the fourth-generation ...

BOSTON -- Contemporary practice had the fourth-generation MitraClip producing low short-term mortality and other good results even in mitral regurgitation (MR) patients previously deemed unsuitable ...

Abbott Laboratories ABT recently received the CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair (TMVR) System, MitraClip G4. It is a renowned minimally invasive mitral ...

The US Food and Drug Administration and Abbott are warning physicians about the potential for clip lock malfunctions with MitraClip G4 and MitraClip NTR/XTR devices. The incidents have been observed ...

ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip™ Transcatheter Mitral Valve Repair System, the leading ...

ABBOTT PARK, Ill. - Abbott today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral ...

PHOENIX -- Newer MitraClip devices reduced mitral regurgitation (MR) to no more than a trace for nearly all patients, regardless of anatomical complexity or presence of advanced heart failure, in a ...

Abbott has received a European approval for the latest generation of its MitraClip device for repairing leaky heart valves. The CE mark for the system’s fourth iteration follows a July 2019 approval ...

Please provide your email address to receive an email when new articles are posted on . At 1 year, a transcatheter edge-to-edge repair device reduced mitral regurgitation to mild or less in 92.6% of ...

Versions of the device have been available in the EU since 2008. The G4 had already been approved for use in the U.S. by the Food and Drug Administration. It treats mitral regurgitation, a condition ...